Andris Jegorovs has stepped down from his role as board member at the Latvian pharmaceutical manufacturer AS 'Olpha', as reported by 'Firmas.lv'. His resignation adds to the leadership changes at the company, which continues to be led by board chairman Juris Hmeļņickis and board member Inga Liščika. This shift comes in a challenging economic environment, as the company is facing a significant decline in both revenue and profits over the past year.

In 2024, Olpha reported a revenue of 126.874 million euros, representing a decrease of 2.9% compared to the previous year, while its profits fell by 28% to 38.648 million euros. Moreover, the company's own operations in the same year registered a revenue of 100.782 million euros, reflecting a more substantial drop of 10.6% from 2023. These financial struggles highlight the pressures faced by the pharmaceutical industry, which has been grappling with various economic challenges, impacting sales and profit margins.

Founded in 1991, Olpha specializes in the production of finished dosage forms, pharmaceutical preparations, nutritional supplements, and active pharmaceutical ingredients. It is owned by the parent company AS 'AB City', which has been a significant player in the Latvian pharmaceutical sector. The company’s current market dynamics, coupled with the recent changes in its leadership, may lead to further evaluations and strategic adjustments in the coming months to address the ongoing financial challenges.